search
Back to results

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Primary Purpose

Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma

Status
Active
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
maplirpacept (PF-07901801)
Pegylated Liposomal Doxorubicin (PLD)
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ovarian Cancer focused on measuring Epithelial Ovarian Cancer (EOC), Ovarian Cancer, Platinum-Resistant Ovarian Cancer, Cluster of Differentiation 47 (CD47), maplirpacept (PF-07901801), TTI-622, Doxorubicin, Immune-oncology, chemotherapy, anti-SIRPα therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Histologically-confirmed epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC).
  • Platinum-resistant disease (progression ≥1 month and ≤6 months after a minimum of four cycles of last platinum-based treatment)
  • Progression with standard of care therapies, including platinum-based therapies, poly ADP ribose polymerase (PARP) inhibitors or bevacizumab in the platinum-sensitive setting or intolerability to such therapies or patient refusal
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Adequate organ and hematologic function
  • No more than four prior treatment regimens for platinum-resistant disease
  • All adverse events from prior treatment must be the Common Terminology Criteria for Adverse Events (NCI CTCAE) v5 Grade ≤ 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline.

Key Exclusion Criteria:

  • Platinum-refractory disease (defined as progression on or within 3 months of completing primary first-line platinum-based treatment)
  • Non-epithelial histology, including malignant mixed Mullerian tumors
  • Ovarian tumors with low malignant potential (i.e., borderline tumors), low grade serous ovarian cancer or carcinosarcoma
  • History of acute coronary syndromes.
  • History of or current Class II, III, or IV heart failure.
  • History or evidence of known central nervous system (CNS) metastases or carcinomatous meningitis.
  • Significant bleeding disorders, vasculitis or a significant bleeding episode from the Gastrointestinal (GI) tract.
  • History of severe hypersensitivity reactions to antibodies.
  • Systemic steroid therapy.
  • History or autoimmune disease that has required systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs.
  • Prior organ transplantation including allogenic or autologous stem cell transplantation
  • Prior treatment with anti-cluster of differentiation 47 (CD47) or anti-SIRPα therapy.

Sites / Locations

  • Sarcoma Oncology Research Center
  • Baptist Hospital of Miami
  • Miami Cancer Institute at Baptist Health, Inc.
  • Orlando Health Cancer Institute Gynecologic Cancer Center
  • Orlando Health Cancer Institute
  • Michigan Healthcare Professionals PC
  • Michigan Healthcare Professionals PC
  • Michigan Healthcare Professionals PC
  • Michigan Healthcare Professionals PC
  • Cleveland Clinic taussig Cancer Center Investigational Pharmacy
  • Cleveland Clinic Fairview Hospital
  • Cleveland Clinic
  • Cleveland Clinic Hillcrest Hospital
  • Oklahoma Cancer Specialist and Research Institute. LLC
  • Magee-Womens Hospital of UPMC
  • UPMC Hillman Cancer Center-Investigational Drug Services
  • Avera Cancer Institute
  • oncology Consultants, P.A.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Phase 1: Dose Escalation

Phase 2: Dose Expansion

Arm Description

In the Phase 1 (dose escalation): Cycle 1 for dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1, Day 8, Day 15 and Day 22 in combination with PLD on Day 1 of 28-day cycle. Beginning with Cycle 2 at dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. For Phase 1, dose level 3, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. Dose level 3 will be biweekly regimen from the start.

In the Phase 2 (dose expansion): maplirpacept (PF-07901801) will be administered with selected dose from the escalation phase by intravenous infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and 15 in subsequent cycles in combination with Pegylated Liposomal Doxorubicin 40 mg/m2 by intravenous infusion on Day 1 of each 28-day cycle.

Outcomes

Primary Outcome Measures

Evaluate DLTs (number) of each escalating dose level of cycle 1 of maplirpacept (PF-07901801) when administered in combination with 40 mg/m2 PLD in 28-day cycles in the Phase 1 escalation
DLTs assessments - defined TEAEs occur during Cycle 1, including specified treatment-related hematologic/non-hematologic toxicities, and other grade ≥2 treated-related non-hematologic toxicities that require a permanent dose reduction or discontinuation of maplirpacept (PF-07901801).
Identify the maximum tolerated dose (MTD) from the Phase 1 Escalation Phase
Determine MTD from Phase 1 Dose Escalation Phase
Identify the Recommended Phase 2 Dose (RP2D) from the Phase 1 Escalation Phase
Determine the Recommended Phase 2 Dose (RP2D) for Phase 2 Dose Expansion Phase
Assess preliminary evidence of anti-tumor activity of (RP2D) maplirpacept (PF-07901801) in combination with 40 mg/m2 PLD (Phase 2 portion of study)
Objective response (CR, PR) as defined by RECIST v1.1 criteria

Secondary Outcome Measures

Assess Duration of progression-free survival (PFS) of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Characterize progression-free survival (PFS) as defined by RECIST v1.1 criteria in the Phase 2 expansion
Assess Overall Survival (OS) of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
The length of overall survival will be measured from the date of study treatment initiation until the date of death from any cause.
Assess Disease Control (DC) [CR+PR+SDS] of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Characterize Disease Control (DC) [CR+PR+SD] as defined by RECIST v1.1 criteria in the Phase 2 expansion
Assess Duration of response (DOR) of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Characterize duration of response (DOR) as defined by RECIST v1.1 criteria.
Further assess the overall safety profile of maplirpacept (PF-07901801) administered in combination with 40 mg/m2 PLD
Characterize by overall safety profiles of adverse events as assessed by: . type . frequency . severity . timing . causal relationship
Number and percentage of events with abnormalities in Electrocardiogram (ECG) findings.
Characterize the overall safety profile as assessed by the number/percentage, timing and relationship of events with abnormal Electrocardiogram (ECG) findings.
Number/percentage, and severity, timing and relationship of hematology, serum chemistry or other laboratory assessments abnormalities (events)
Characterize the overall safety profile as assessed by number/percentage, the severity (CTCAE version 5), timing and relationship of abnormal hematology, serum chemistry or other laboratory assessments
Number/percentage, and severity, timing and relationship of abnormal changes in the vital signs events
Characterize the overall safety profile as assessed by number/percentage, the severity (CTCAE version 5), timing and relationship of abnormal changes in the vital signs' events.
Evaluate safety profile by number/percentage of treatment delays.
Characterize the overall safety profile as assessed by treatment delays.
Evaluate safety profile by number/percentage of treatment discontinuation
Characterize the overall safety profile as assessed by treatment discontinuation

Full Information

First Posted
November 22, 2021
Last Updated
September 28, 2023
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT05261490
Brief Title
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Official Title
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
December 9, 2024 (Anticipated)
Study Completion Date
December 9, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer. However, despite being consider a standard treatment option, the clinical benefit of chemotherapy alone for these patients is small. Historically, response rates for PLD monotherapy have only ranged from 12 to 35% with a high likelihood of recurrence within months after treatment initiation. Although bevacizumab (BEV), an anti-new-vascular growth monoclonal antibody has been approved by FDA to combine with standard chemotherapy (e.g., PLD) for platinum-resistant recurrent ovarian cancer, there are still many restrictions or contraindications preventing certain women from receiving bevacizumab's combination treatment. The goal of this study is to improve upon the activity of PLD in a safe manner to provide a more effective therapeutic option for this group of patients. The purpose of this study is to assess maplirpacept (PF-07901801) administered in combination with PLD in patients with platinum-resistant ovarian cancer and for whom PLD is a reasonable treatment option. The first portion of the study will evaluate the safety of increasing dose levels of maplirpacept (PF-07901801) in combination with PLD at 40 mg/m2 in patients with platinum-resistant EOC (epithelial ovarian cancer). This is a group of cancer, including ovarian, peritoneal, and fallopian tube malignancy. The aim of the first portion of the study is to establish a combination regimen for further assessment in a dose expansion cohort. The study will consist of a 28-day screening period to ensure participants are qualified for the study treatment plan. During the treatment period, patients will receive maplirpacept (PF-07901801) in combination with PLD in 28-day cycles until their disease progresses or unacceptable toxicity develops. There will be a long-term follow-up period in this study to assess overall survival (length of time since start of treatment patients are alive).
Detailed Description
Pegylated liposomal doxorubicin (PLD) is a standard treatment option for patients with platinum-resistant ovarian cancer who are not candidates for chemotherapy in combination with bevacizumab. However, despite being consider a standard treatment option, the clinical benefit of chemotherapy for this patient population is small. The goal of this clinical trial is to improve upon the activity of PLD in a safe manner to provide a more effective therapeutic option for this group of patients. C4971002 (TTI-622-02) is a multi-center, open-label study designed to evaluate maplirpacept (PF-07901801) administered in combination with PLD in patients with platinum-resistant ovarian cancer and for whom PLD is a reasonable treatment option. The first portion of the study will evaluate the safety of increasing dose levels of maplirpacept (PF-07901801) in combination with PLD at 40 mg/m2 in patients with platinum-resistant EOC, including ovarian, peritoneal and fallopian tube malignancy, and establish a combination regimen for further evaluation in a dose expansion cohort. The study will consist of a 28-day screening period, a treatment period in which patients will receive maplirpacept (PF-07901801) in combination with PLD in 28-day cycles until documentation of objective disease progression or development of unacceptable toxicity, and a long-term follow-up period to assess overall survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Keywords
Epithelial Ovarian Cancer (EOC), Ovarian Cancer, Platinum-Resistant Ovarian Cancer, Cluster of Differentiation 47 (CD47), maplirpacept (PF-07901801), TTI-622, Doxorubicin, Immune-oncology, chemotherapy, anti-SIRPα therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Phase 1/2 (dose escalation and dose expansion)
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase 1: Dose Escalation
Arm Type
Experimental
Arm Description
In the Phase 1 (dose escalation): Cycle 1 for dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1, Day 8, Day 15 and Day 22 in combination with PLD on Day 1 of 28-day cycle. Beginning with Cycle 2 at dose levels 1 and 2, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. For Phase 1, dose level 3, maplirpacept (PF-07901801) will be administered on Day 1 and Day 15 in combination with PLD on Day 1 of 28-day cycles. Dose level 3 will be biweekly regimen from the start.
Arm Title
Phase 2: Dose Expansion
Arm Type
Experimental
Arm Description
In the Phase 2 (dose expansion): maplirpacept (PF-07901801) will be administered with selected dose from the escalation phase by intravenous infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and 15 in subsequent cycles in combination with Pegylated Liposomal Doxorubicin 40 mg/m2 by intravenous infusion on Day 1 of each 28-day cycle.
Intervention Type
Drug
Intervention Name(s)
maplirpacept (PF-07901801)
Other Intervention Name(s)
TTI-622
Intervention Description
PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
Intervention Type
Drug
Intervention Name(s)
Pegylated Liposomal Doxorubicin (PLD)
Other Intervention Name(s)
PLD
Intervention Description
RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
Primary Outcome Measure Information:
Title
Evaluate DLTs (number) of each escalating dose level of cycle 1 of maplirpacept (PF-07901801) when administered in combination with 40 mg/m2 PLD in 28-day cycles in the Phase 1 escalation
Description
DLTs assessments - defined TEAEs occur during Cycle 1, including specified treatment-related hematologic/non-hematologic toxicities, and other grade ≥2 treated-related non-hematologic toxicities that require a permanent dose reduction or discontinuation of maplirpacept (PF-07901801).
Time Frame
DLTs during the DLT observation period (28 days following C1D1)
Title
Identify the maximum tolerated dose (MTD) from the Phase 1 Escalation Phase
Description
Determine MTD from Phase 1 Dose Escalation Phase
Time Frame
First dose up to 1 year
Title
Identify the Recommended Phase 2 Dose (RP2D) from the Phase 1 Escalation Phase
Description
Determine the Recommended Phase 2 Dose (RP2D) for Phase 2 Dose Expansion Phase
Time Frame
First dose up to 1 year
Title
Assess preliminary evidence of anti-tumor activity of (RP2D) maplirpacept (PF-07901801) in combination with 40 mg/m2 PLD (Phase 2 portion of study)
Description
Objective response (CR, PR) as defined by RECIST v1.1 criteria
Time Frame
First dose up to 2 years
Secondary Outcome Measure Information:
Title
Assess Duration of progression-free survival (PFS) of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Description
Characterize progression-free survival (PFS) as defined by RECIST v1.1 criteria in the Phase 2 expansion
Time Frame
First Dose up to 3 years
Title
Assess Overall Survival (OS) of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Description
The length of overall survival will be measured from the date of study treatment initiation until the date of death from any cause.
Time Frame
First Dose up to 3 years
Title
Assess Disease Control (DC) [CR+PR+SDS] of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Description
Characterize Disease Control (DC) [CR+PR+SD] as defined by RECIST v1.1 criteria in the Phase 2 expansion
Time Frame
First Dose up to 3 years
Title
Assess Duration of response (DOR) of maplirpacept (PF-07901801) (RP2D) in combination with PLD 40mg/m2 in 28-day cycle in the Phase 2 expansion
Description
Characterize duration of response (DOR) as defined by RECIST v1.1 criteria.
Time Frame
First Dose up to 3 years
Title
Further assess the overall safety profile of maplirpacept (PF-07901801) administered in combination with 40 mg/m2 PLD
Description
Characterize by overall safety profiles of adverse events as assessed by: . type . frequency . severity . timing . causal relationship
Time Frame
First Dose up to 2 years
Title
Number and percentage of events with abnormalities in Electrocardiogram (ECG) findings.
Description
Characterize the overall safety profile as assessed by the number/percentage, timing and relationship of events with abnormal Electrocardiogram (ECG) findings.
Time Frame
First dose up to 3 years
Title
Number/percentage, and severity, timing and relationship of hematology, serum chemistry or other laboratory assessments abnormalities (events)
Description
Characterize the overall safety profile as assessed by number/percentage, the severity (CTCAE version 5), timing and relationship of abnormal hematology, serum chemistry or other laboratory assessments
Time Frame
First Dose up to 3 years
Title
Number/percentage, and severity, timing and relationship of abnormal changes in the vital signs events
Description
Characterize the overall safety profile as assessed by number/percentage, the severity (CTCAE version 5), timing and relationship of abnormal changes in the vital signs' events.
Time Frame
First Dose up to 3 years
Title
Evaluate safety profile by number/percentage of treatment delays.
Description
Characterize the overall safety profile as assessed by treatment delays.
Time Frame
First dose up to 3 years
Title
Evaluate safety profile by number/percentage of treatment discontinuation
Description
Characterize the overall safety profile as assessed by treatment discontinuation
Time Frame
First dose up to 3 years

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 Histologically-confirmed epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC). Platinum-resistant recurrent (disease progression ≤6 months after the most recent platinum-based treatment regimen (date calculated from the last administered dose of platinum) or the participant is no longer able to receive. or declined treatment with platinum-based chemotherapy. Progression with standard of care therapies, including platinum-based therapies, poly ADP ribose polymerase (PARP) inhibitors or bevacizumab in the platinum-sensitive setting or intolerability to such therapies or patient refusal Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Adequate organ and hematologic function No more than four prior treatment regimens for platinum-resistant disease All adverse events from prior treatment must be the Common Terminology Criteria for Adverse Events (NCI CTCAE) v5 Grade ≤ 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline. Key Exclusion Criteria: Platinum-refractory disease (defined as progression on or within 3 months of completing primary first-line platinum-based treatment) Non-epithelial histology, including malignant mixed Mullerian tumors Ovarian tumors with low malignant potential (i.e., borderline tumors), low grade serous ovarian cancer or carcinosarcoma History of acute coronary syndromes. History of or current Class II, III, or IV heart failure. History or evidence of known central nervous system (CNS) metastases or carcinomatous meningitis. Significant bleeding disorders, vasculitis or a significant bleeding episode from the Gastrointestinal (GI) tract. History of severe hypersensitivity reactions to antibodies. Systemic steroid therapy. History or autoimmune disease that has required systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs. Prior organ transplantation including allogenic or autologous stem cell transplantation Prior treatment with anti-cluster of differentiation 47 (CD47) or anti-SIRPα therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Sarcoma Oncology Research Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90403
Country
United States
Facility Name
Baptist Hospital of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Miami Cancer Institute at Baptist Health, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Orlando Health Cancer Institute Gynecologic Cancer Center
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Orlando Health Cancer Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Michigan Healthcare Professionals PC
City
Dearborn
State/Province
Michigan
ZIP/Postal Code
48126
Country
United States
Facility Name
Michigan Healthcare Professionals PC
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48334
Country
United States
Facility Name
Michigan Healthcare Professionals PC
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
Michigan Healthcare Professionals PC
City
Sterling Heights
State/Province
Michigan
ZIP/Postal Code
48314
Country
United States
Facility Name
Cleveland Clinic taussig Cancer Center Investigational Pharmacy
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Cleveland Clinic Fairview Hospital
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44111
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Cleveland Clinic Hillcrest Hospital
City
Mayfield Heights
State/Province
Ohio
ZIP/Postal Code
44124
Country
United States
Facility Name
Oklahoma Cancer Specialist and Research Institute. LLC
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74146
Country
United States
Facility Name
Magee-Womens Hospital of UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
UPMC Hillman Cancer Center-Investigational Drug Services
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
Avera Cancer Institute
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57105
Country
United States
Facility Name
oncology Consultants, P.A.
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
IPD Sharing URL
https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Links:
URL
https://pmiform.com/clinical-trial-info-request?StudyID=TTI-622-02
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

We'll reach out to this number within 24 hrs